Table 1.
Baseline Characteristics of Enrolled Participants
| Efavirenz/FTC/TDF by CYP2B6 Metabolizer Genotype | Dolutegravir/FTC/TDF (n = 342) | |||
|---|---|---|---|---|
| Extensive (n = 49) | Intermediate (n = 74) | Slow (n = 45) | ||
| Age (y), median (IQR) | 32 (26–37) | 31 (27–36) | 33 (29–37) | 32 (27–37) |
| Sex (women), n (%) | 25 (51.0) | 47 (63.5) | 22 (48.9) | 199 (58.2) |
| Race (Black), n (%) | 49 (100) | 74 (100) | 45 (100) | 342 (100) |
| BMI (kg/m 2 ), median (IQR) | 21.4 (19.7–25.2) | 24.4 (21.4–28.3) | 23.9 (20.4–27.5) | 22.9 (20.1–27.0) |
| CD4 count (cells/µL), median (IQR) | 286 (181–381) | 303 (176–417) | 261 (159–384) | 274 (160–424) |
| HIV-1 RNA (log 10 ), median (IQR) | 4.4 (3.9–4.8) | 4.3 (3.5–5.1) | 4.6 (4.0 to 5.1) | 4.4 (3.8–4.9) |
Abbreviations: BMI, body mass index; FTC, emtricitabine, HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; TDF, tenofovir disoproxil fumarate.